Life Science News

RSS

Study identifies genetic associations with youth psychopathology

When trying to understand how genetic influences factor into youth behavior, researchers at Washington University in St. Louis have taken the "big trawl" approach, casting their net wide to pull in all the measured traits, behaviors and environments that make up who we are and examine associations with the genetic building blocks comprising risk for mental health problems.

17 Oct 2024

Brazil-Italy joint lab focuses on Alzheimer’s drug development

A self-proclaimed Brazil-Italy collaboration enthusiast, researcher Laura Bolognesi created the B2AlzD2 Joint Lab at the Department of Pharmacy and Biotechnology of the Università di Bologna (UNIBO), the first Brazil-Bologna joint laboratory dedicated to the development of new drugs for the treatment of Alzheimer's disease.

17 Oct 2024

New synthesis technology promises faster production of mRNA vaccines

In an era where viral outbreaks can escalate into global pandemics with alarming speed, the ability to quickly develop new vaccines has become crucial.

17 Oct 2024

Discovering new natural products from human microbiomes

The idea of using microorganisms as a source of new active ingredients is not new. Numerous drugs have already been developed on the basis of natural products from bacteria and fungi.

17 Oct 2024

New genetic variant may predict severe ulcerative colitis in patients

Abdominal pain, diarrhea, and debilitating fatigue define the daily lives of millions of people worldwide who suffer from chronic bowel disease.

17 Oct 2024

Adenine base editors show potential to correct X-CGD-causing mutations

A collaborative effort between investigators at the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder characterized by high susceptibility to infections.

16 Oct 2024

Molecular chaperones as key players in tumor suppressor stability

A new review was published in Oncotarget's Volume 15 on October 1, 2024, entitled, "Molecular chaperones: Guardians of tumor suppressor stability and function."

16 Oct 2024

Enhancing mRNA lifespan: A step forward in therapeutic development

mRNA-based therapeutics and vaccines are the new hope in the fight against incurable diseases. A commonly used strategy in the development of messenger RNA (mRNA) medicine is based on the destruction of disease-causing mRNA.

16 Oct 2024

Male mice use female distraction to deescalate aggression, study finds

A research group led by Joshua Neunuebel at the University of Delaware, USA, tracked the behavior of mice using machine learning to understand how they handle aggressive behavior from other mice.

16 Oct 2024

Study reveals genetic factors affecting birth sex ratios

Each year, roughly the same numbers of boys and girls are born.

16 Oct 2024

Two programs found to control invasion and inflammation in segregated tumor cell populations

Understanding in depth how tumors evolve to become malignant is the objective of the latest study led by the Cell Plasticity in Development and Disease laboratory, directed by ángela Nieto at the Institute for Neurosciences (IN), a joint center of the Spanish National Research Council (CSIC) and the Miguel Hernández University (UMH) of Elche.

16 Oct 2024

Innovative approach to measure acetaminophen in human urine

In recent years, the excessive use of acetaminophen (APAP) has become a significant human hazard and social burden.

16 Oct 2024

Bacteriophages unveil auxiliary genes critical for infection

Viruses that infect bacteria—known as bacteriophages - could be used in a targeted manner to combat bacterial diseases.

16 Oct 2024

Cellular Origins, Fresenius Kabi sign development agreement for scalable automation of cell and gene therapy manufacturing

Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs).

16 Oct 2024

Transposons play essential role in early human development

A critical transition in early human development is regulated not by our own genes, but by DNA elements called transposons that can move around the genome, Sinai Health researchers have found.

16 Oct 2024

Induced resistance as a path to sustainable food security

As the climate crisis alters familiar growing conditions, we urgently need to find ways of protecting the world against famines.

16 Oct 2024

Shift Bioscience raises $16 M to advance cell simulation AI platform

Shift Bioscience is a biotech company using generative AI models to understand how activation of different genes can reverse the aging process. This research is a fundamental step forward in designing more effective drugs to treat age-related diseases.

From Shift Bioscience 16 Oct 2024

Refeyn introduces new mass photometry products to streamline biomolecular analysis workflows

Refeyn, the company behind pioneering mass photometry technologies, has taken another step to assure mass photometry is a simpler, more efficient bioanalytics tool with the release of a powerful expansion of its consumables portfolio.

From Refeyn 16 Oct 2024

Antibody engineering drives innovation in drug development

Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable and communicable diseases. Over the past few years, the market for mAbs has grown exponentially with an expected compound annual growth rate (CAGR) of 11.07% from 2024 (237.64 billion USD estimated at the end of 2023) to 2033 (679.03 billion USD expected by the end of 2033).

16 Oct 2024

Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery

Ubiquigent Limited (“Ubiquigent”), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced a strategic partnership with Alleo Labs Corp. (“Alleo”), a pioneer in using artificial intelligence (AI) to develop new therapeutics for neurological diseases.

From Ubiquigent Limited 16 Oct 2024